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Introduction
Effective population-based screening requires adequate
compliance among the target population [1]. The goal of
the UK breast screening programme, a 25% reduction in
mortality, required first-screen compliance to be 70%
[2,3]. This target was exceeded in many areas throughout
CI = confidence interval; HRT = hormone replacement therapy; OR = odds ratio.
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Abstract
Background: One area of concern within the largely successful UK National Health Service breast
screening programme is the relatively high proportion of women showing mammographic abnormalities
who undergo further diagnostic tests that prove negative. Previous studies suggest that, in addition to
increasing anxiety, such false-positive mammography is associated with increased risk of subsequent
interval cancer. In the present article, we quantify this increased risk, investigate whether it extends to
cancers detected at rescreening, and determine whether cancers differ between women who have,
and have not, experienced false-positive mammography.
Methods:  This was a retrospective cohort study of 140,387 women aged 49–63 years routinely
invited for first screening by the East Anglian National Health Service breast screening programme.
Proportions reattending, and subsequent risk and pathological attributes of cancer were compared
between women who underwent further (negative) assessment following false-positive mammography
and women mammographically normal at first screen.
Results: At first screen, 108,617 (91.9%) of the screened women were mammographically normal,
4278 (3.6%) were assessed and then judged normal, and 514 (0.4%) underwent benign biopsy.
Compared with nonassessed normal women, reattendance was lower among assessed women: 83.1%
(95% confidence interval [CI], 82.0–84.1) versus 85.7% (95% CI, 85.5–85.9) (odds ratio [OR], 0.82;
95% CI, 0.76–0.89). Assessed women were at greater risk of interval cancer (rate per 1000 women
screened, 9.6 [95% CI, 6.8–12.4] versus 3.0 [95% CI, 2.7–3.4]; OR, 3.19 [95% CI, 2.34–4.35]), and
also of cancer detected at second screen (rate per 1000, 8.4 [95% CI, 5.8–10.9] versus 3.9 [95% CI,
3.5–4.3]; OR, 2.15 [95% CI, 1.55–2.98]). More cancers in assessed women measured ≥20 mm (OR,
1.59; 95% CI, 0.99–2.55).
Conclusions: Women undergoing false-positive mammography at first screen were less likely to reattend
for subsequent screens than were nonassessed women, yet they were more likely to develop interval
cancers or cancers at second screen, and their cancers were larger. Factors predisposing for false-
positive mammography require investigation. Women should be encouraged to continue with screening.
Keywords: breast screening, false-positive mammography, interval cancer, screen-detected cancer, screening
attendance
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the UK [4]. Another key prerequisite to maintaining a suc-
cessful screening programme is acceptability, and the
≥90% reattendance rate among previous screenees indi-
cated high acceptability in UK women [4].
Despite meeting most of the targets set, however, breast
screening in the UK has not been an unmitigated success
story. When screening was introduced there were reports
of increased anxiety among the large numbers of women
undergoing assessment following positive screening
mammography [5]. Although most women do not show
abnormalities on their screening mammograms and are
simply asked to return for rescreening in 3 years, the
mammograms of 5–9% of all women indicate possible
malignancy. These women must undergo a second
‘assessment’ phase of the screening process, which
involves further procedures such as ultrasound, needle
biopsy and, possibly, open biopsy to establish a definitive
diagnosis. As expected, malignancy is ruled out for the
majority of women assessed, indicating that the result of
their mammography was falsely positive. In the current
study, the term ‘false positive’ is thus applied to any
woman who is recalled for assessment on the basis of
mammographic findings and in whom cancer is not diag-
nosed. Other studies may limit use of the term only to
those women who have undergone open biopsy with no
resultant diagnosis of cancer.
Although some studies have indicated that false-positive
mammography does not deter women from reattending
[6–8], it clearly has associated financial and psychological
costs. Furthermore, ourselves [9] and other workers [10]
have found that women judged false positive at first
screen are more likely to develop an interval cancer before
the second screening is due. To assess the impact of
false-positive mammography on screening effectiveness,
we investigate whether false-positive mammography
affects subsequent reattendance in East Anglia. We quan-
tify the magnitude of the increased risk of interval cancer,
and extend these investigations to determine whether
false-positive mammography at first screen increases the
risk of cancer detected at second screen. Finally, we
compare the pathology of cancers presenting in women
who have undergone false-positive mammography with
that of cancers in women judged normal at the preceding
screening.
Methods
Screening was introduced in East Anglia over the period
1989–1991. Women were invited by year of birth, in 5-
year age groups [11]. The first round of screening
occurred in 1989–1995, and the second occurred 3 years
later (1992–1998). All women invited to the first round,
and eligible for reinvitation to the second, were identified
on the breast screening computer system. The majority
was aged 50–62 years. Those aged 63–64 years were
beyond the invited age range at the time of the second
screen and were excluded. We only included women
invited on schedule (i.e. within 24 months of commencing
invitation of the relevant birth cohort) in order to exclude
women who failed to respond at first invitation but who
attended for the first time on reinvitation 3 years later [12].
Women were followed up from the date of first invitation
until invitation to the second screening if within 3.5 years
(i.e. 1277 days), or for the mean interscreen interval for
the screening unit if no screen occurred within this time
(mean ± standard error interscreen interval for all regional
screening units, 1106 ± 7.6 days). Interval and screen-
detected cancers were identified by matching screening
unit and Cancer Registry databases as described previ-
ously [12]. Women not attending within 6 months of the
first invitation were deemed to have refused screening.
With the exception of women attending for the first invita-
tion within 6 months but placed on early recall, only those
women whose second screening episode (either
accepted or refused) was completed within 3.5 years of
the first invitation are considered in the present analysis.
Information on prognostic characteristics size (maximum
diameter of invasive component), grade [13], node status
and histological subtype [14] was obtained from the
Cancer Registry, from screening units and from medical
records. Cancers were assigned a prognostic risk group
[9], based on histological type and malignancy grade
[15–17]. Differences in distribution of these attributes,
and of the risk of cancer, among study groups were
expressed as ORs [18].
Study groups
Table 1 presents the relationship of the study groups to
the total population of 203,194 women eligible for invita-
tion to the first screening round. Of these women,
140,387 (69.1%) were identified as first-round invitees
who were invited within schedule and were eligible for
reinvitation to rescreening.
Of these 140,387 women, 118,216 (84.2%) completed a
satisfactory first screen within 6 months of the first
appointment. At first appointment, 108,617 (77.4%) were
judged normal on the basis of mammography alone (the
‘non-assessed normal’ group). Of 6460 (4.6%) women
who underwent further assessment to establish definitive
diagnosis, 6337 were investigated immediately; the
remainder underwent further appointments for technical
reasons or through failure to respond to invitations. Of
those assessed immediately, 4278 women were judged
normal at assessment (‘assessed normal’ group), and 514
proceeded to open biopsy, the result of which was benign
(‘assessed benign’ group). Women in assessed normal
and assessed benign groups returned directly to routine
screening. Overall, there were 113,409 women in thePage 3 of 9
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nonassessed normal, assessed normal and assessed
benign study groups, comprising 80.8% of all women who
were invited for a routine first screen within schedule and
were eligible for reinvitation to the second round.
The mean ± standard deviation age of women was similar
in all study groups: 56.0 ± 3.5 years in the entire invited
cohort eligible for reinvitation, 55.8 ± 3.5 years in the
nonassessed normal group, 56.1 ± 3.5 years in the
assessed normal group, and 56.4 ± 3.6 years in the
assessed benign group.
Of the 6337 women assessed immediately following the
first screen, 680 were initially diagnosed with cancer. A
further 11 women were diagnosed following initial nonat-
tendance at assessment, and 22 at early recall. This pro-
duced a total of 713 women. Of the 680 women
diagnosed at initial assessment, 676 were registered at
the Cancer Registry. The remaining four women were
either recurrences of earlier breast primaries or other
malignancies not classified as primary breast cancer (e.g.
cytosarcoma phyllodes) [19,20].
Results
Numbers of cases, rates per 1000 screened, and odds of
presenting with interval cancer or having a cancer
detected at second screen are presented by study group
in Table 2. In all study groups combined, 375 interval
cancers presented and 463 cancers were detected at
second screen. The risk of subsequent interval cancer, or
cancer detected at second screen, was higher in women
assessed at the preceding screen. The OR among all
assessed women for an interval cancer arising was 3.19
(95% CI, 2.34–4.35) compared with the nonassessed
normal group, and that for detecting a cancer at second
screen was 2.15 (95% CI, 1.55–2.98). Compared with
the nonassessed normal group, the OR of a second round
screen-detected cancer in the assessed benign group
was lower, but the difference was not significant, possibly
due to the small size of the assessed benign group (OR,
0.50; 95% CI, 0.07–3.55).
Numbers and proportions of women with appointments
for, and attending, the second screen are presented, by
study group and interval cancer status, in Table 3, which
also presents the ORs for the likelihood of recorded
appointments and reattendance. Explanations for a lack of
recorded reinvitation appointment include deletion of
appointments cancelled in advance, and removal of
women from the invitation list following moving house,
bilateral mastectomy or death. Overall, 90.6% of women
had recorded appointments for a second screen within
3.5 years, and 85.6% reattended. Compared with the
nonassessed normal group, the proportion with recorded
appointments was slightly lower among the assessed
normal group (OR, 0.78; 95% CI, 0.71–0.86) and was
lower still among the assessed benign group (OR, 0.51;
95% CI, 0.41–0.65) (see Table 3). Reattendance was
similarly slightly lower among women in the assessed
normal group (OR, 0.84; 95% CI, 0.78–0.92) compared
Available online http://breast-cancer-research.com/content/4/5/R11
Table 1
Relationship of study groups to total population of women eligible for and invited to the first screening round in East Anglia
Group Number Percent
All women eligible for screening in the first round 203,194 100.0
Those not aged 49–63 years and hence ineligible for reinvitation to the second round 337,668 16.6
Those not invited as routine first screen 7272 3.6
Those not invited within schedule (see Methods) 21,769 10.7
Those eligible for reinvitation, invited as routine first screen, within schedule 140,387 69.1
Those eligible for reinvitation, invited as routine first screen, within schedule 140,387 100.0
Those judged normal at first screen (nonassessed normal group)a 108,617 77.4
Nonresponders to first invitation 24,048 17.0
Technical (and clinical) recalls 1385 1.0
Those assessed immediately after first screen and judged normal (assessed normal group)a 4278 3.0
Those assessed immediately after first screen then undergoing benign biopsy (assessed benign group)a 514 0.4
Those assessed immediately after first screen then diagnosed with cancer 680 0.5
Those assessed immediately after first screen and put on early recall 753 0.5
Those assessed immediately after first screen then undergoing delayed episode completion 
(includes nonresponders, delayed responders, those who moved or died, etc.) 112 0.1
a Total in study groups (nonassessed normal + assessed normal + assessed benign) = 113,409 (80.8% of total study population).with the nonassessed normal group, and was lower still
among the assessed benign group (OR, 0.65; 95% CI,
0.52–0.81). Reattendance among women with recorded
reinvitation appointments was similar in all groups
(94–95%, calculated from data in Table 3).
Reattendance was much lower among women presenting
with interval cancer following the first screen. Combining
assessed and nonassessed women, 90.8% of women
without interval cancer had reinvitation appointments
recorded, and 85.8% actually reattended, whereas only
27.2% of women with interval cancer had reinvitation
appointments, and 19.2% reattended (see Table 3).
Among the 680 women diagnosed with cancer immedi-
ately following first screen, similarly low proportions with
reinvitation appointments (250 of 680 women [36.8%])
and reattending (224 of 680 women [32.9%]) were
observed (data not shown).
The effects of the study group on pathological attributes
of interval cancers and second round screen-detected
cancers are presented in Table 4. Interval cancers and
cancers detected at second screen in assessed women
were larger compared with cancers in nonassessed
women, with more measuring at least 20 mm (OR, 1.59;
95% CI, 0.99–2.55). This effect reached statistical signifi-
cance in the assessed normal group (OR, 1.63; 95% CI,
1.01–2.64). There were no significant differences
between assessed and nonassessed women in risk of
high grade (grade 3) cancers. Compared with the
nonassessed normal group, there were some indications
of fewer high grade interval cancers among those
assessed (OR, 0.47; 95% CI, 0.17–1.28), but this was
not statistically significant. Cancers detected at second
screen in women who were assessed at first screen
showed some indication of increased risk of positive
nodes (OR, 1.51; 95% CI, 0.67–3.39). There was a non-
significant increase in numbers of advanced stage (stage
2+) interval and second round screen-detected cancers in
assessed women (OR, 1.32; 95% CI, 0.83–2.11). Interval
cancers in the assessed normal group showed a slightly
increased tendency to present in the left breast (OR, 1.51;
95% CI, 0.77–2.95). For interval cancers, the likelihood of
a cancer being of high prognostic risk (group 3) was sig-
nificantly lower in the assessed normal group than in the
nonassessed group (OR, 0.34; 95% CI, 0.12–0.99).
Discussion
False-positive mammography is a relatively frequent occur-
rence within breast screening programmes. It was calcu-
lated that, during 10 years in New England, USA, one-third
of women screened by mammography and clinical exami-
nation underwent false-positive screening [21]. Last year
in the UK there were around 11 unnecessary recalls for
every cancer detected within the National Health Service
breast screening programme (8.3% of women assessed
at first screen, 6.7 cancers detected per 1000 screened;
7.6% false-positive at first mammography) [4]. This figure
fell to around six recalls for every cancer detected at
repeat screening (3.9% of women assessed, 5.5 cancers
detected per 1000 screened; 3.4% false-positive at subse-
quent mammography) [4]. For a woman attending all five
Breast Cancer Research    Vol 4 No 5 McCann et al.
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Table 2
Likelihood of presentation of interval cancer following an initial screen, and of detection of cancer by screening at the second
screening round, by assessment status
Women with/without cancer
Rate with per  Odds ratio 
Study group Total (n) With (n) Without (n) 1000 screened (95% CI) (95% CI)
Women with/without interval cancer
All groups 113,409 375 113,034 3.31 (2.97–3.64) –
Nonassessed normal 108,617 329 108,288 3.03 (2.70–3.35) 1.00
Assessed normal 4278 42 4236 9.82 (6.86–12.77) 3.26 (2.36–4.51)
Assessed benign 514 4 510 7.78 (0.19–15.38) 2.58 (0.96–6.95)
All assessed 4792 46 4746 9.60 (6.83–12.36) 3.19 (2.34–4.35)
Women with/without second round screen-detected cancer
All groups 113,409 463 112,946 4.08 (3.71–4.45) –
Nonassessed normal 108,617 423 108,194 3.89 (3.52–4.26) 1.00
Assessed normal 4278 39 4239 9.12 (6.27–11.96) 2.35 (1.69–3.27)
Assessed benign 514 1 513 1.95 (0–5.75) 0.50 (0.07–3.55)
All assessed 4792 40 4752 8.35 (5.77–10.92) 2.15 (1.55–2.98)screens to which she is currently invited, assuming the result
of each screening is independent of any previous result, her
cumulative probability of at least one false-positive screening
is therefore around 19% {1–(P [No. false positives on first
screen] × P [No. false positives on subsequent screen]4)},
i.e. {1 – ([1–0.0763] × [1–0.0335]4)}.
In East Anglia, 4.1% of women screened in the first
screening round and eligible for a second screen under-
went false-positive mammography at first screen. These
women were more than three times as likely as
nonassessed normal women to present with an interval
cancer before the second screen was due, and more than
Available online http://breast-cancer-research.com/content/4/5/R11
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Table 3
Numbers and proportions of cases of interval cancer and second round screen-detected cancer, and likelihood of presentation, by
study group and interval cancer status
Reinvited Reattending
Women (n) Women (n)
Total % Yes  Odds ratioa % Yes  Odds ratioa
Study group (100%) Yes No (95% CI) (95% CI) Yes No (95% CI) (95% CI)
All groups
All 113,409 102,772 10,637 90.6 97,062 16,347 85.6 
(90.5–90.8) (85.4–85.8)
With interval cancer 375 102 273 27.2 72 303 19.2 
(22.7–31.7) (15.2–23.2)
Without interval cancer 113,034 102,670 10,364 90.8  96,990 16,044 85.8 
(90.7–91.0) (85.6–86.0)
Nonassessed normal
All 108,617 98,561 10,056 90.7 1.00 93,081 15,536 85.7 1.00
(90.6–90.9) (85.5–85.9)
With interval cancer 329 97 232 29.5  69 260 21.0 
(24.6–34.4) (16.6–25.4)
Without interval cancer 108,288 98,464 9824 90.9  93,012 9824 85.9 
(90.8–91.1) (85.7–86.1)
Assessed normal
All 4278 3782 496 88.4 0.78  3572 706 83.5  0.84 
(87.4–89.4) (0.71–0.86) (82.4–84.6) (0.78–0.92)
With interval cancer 42 5 37 11.9  3 39 7.1 
(2.1–21.7) (0–14.9)
Without interval cancer 4236 3777 459 89.2  3569 667 84.3 
(88.2–90.1) (83.2–85.4)
Assessed benign
All 514 429 85 83.5 0.51  409 105 79.6  0.65 
(80.3–86.7) (0.41–0.65) (76.1–83.1) (0.52–0.81)
With interval cancer 4 0 4 0 0 4 0
Without interval cancer 510 429 81 84.1  409 101 80.2 
(81.0–87.3) (76.7–83.7)
All assessed
All 4792 4211 581 87.9 0.74  3981 811 83.1  0.82 
(87.0–88.8) (0.68–0.81) (82.0–84.1) (0.76–0.89)
With interval cancer 46 5 41 10.9  3 43 6.5 
(1.9–19.9) (0–13.7)
Without interval cancer 4746 4206 540 88.6  3978 768 83.8 
(87.7–89.5) (82.8–84.9)
a Odds ratios of the likelihood of reinvitation or reattendance among assessed normal, assessed benign or all assessed women versus that in the
nonassessed normal group.Breast Cancer Research    Vol 4 No 5 McCann et al.
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.twice as likely to have a cancer detected at second
screening. If the followup period of the current study had
been extended beyond the interscreen interval, these
women might have continued to show increased risk of
cancer beyond the due date for second screen. The rate
in lapsed attenders who were false positive at first screen
is thus also likely to have been high.
For women who undergo false-positive mammography
and then present with cancer, the validity of the negative
assessment comes into question. Among women in the
current study, 12.3% of those presenting with interval
cancer after the first screen, and 8.6% of those with
cancer detected at second screen, had previously been
assessed compared with the 4.2% of women assessed
of those not diagnosed with cancer. A review of the origi-
nal screening films of women with interval cancers has
shown that around one-fifth of all East Anglian cases
might potentially be prevented through earlier diagnosis
at the previous screening [9]. However, quantification of
the extent to which failure of diagnosis at assessment has
contributed to the interval cancer rate requires detailed
comparison of the site and nature of relevant lesions at
assessment and diagnosis, which was beyond the scope
of the current study.
Another possible explanation for the increased risk of
cancer in women following false-positive mammography
might be that a characteristic of women’s breasts which
makes them difficult to interpret mammographically and
predisposes them to the risk of a false-positive result is
actually itself a risk factor for breast cancer. Such a link
between risk of false-positive mammography and risk of
cancer might be hormone replacement therapy (HRT). Laya
et al. in 1996 [22], and others since [23], demonstrated
that current use of HRT by women aged 50+ years is asso-
ciated both with decreased screening  sensitivity
(increased interval cancers) and decreased specificity
(increased false positives). Furthermore, long-term use of
HRT has been shown to increase breast cancer risk [24].
It has been proposed that these effects of HRT are medi-
ated through high risk (i.e. dense) mammographic patterns
[25], which themselves have been shown to be associ-
ated both with reduced screening specificity [22,26,27]
and with increased risk of breast cancer [28,29]. Unfortu-
nately, information on HRT use among women in the
current study was not available to test this hypothesis. If
found relevant, however, consideration of a woman’s indi-
vidual risk profile might prove helpful in deciding a strategy
for subsequent rescreening.
In addition to being at increased risk of cancer, women
who experienced false-positive mammography were 18%
less likely than those who were genuinely screen normal to
reattend for a second screening. Women who underwent
benign biopsy were even less likely (35%) to return. This
finding was in contrast with reports from previous studies
when false-positive mammography either had no effect on
subsequent attendance [6–8] or, alternatively, actually
increased by 20% the likelihood of future reattendance
[30], even in those who underwent a negative biopsy [31].
As previously suggested [7,32], however, regional varia-
tions in handling of assessment procedures and false-posi-
tive cases may explain differences in uptake of screening
reinvitations. Such findings suggest that the figures may be
amenable to improvement through a change in practice.
The reduced reattendance among women with false-posi-
tive mammography was accompanied by a reduced likeli-
hood of reinvitation appointments recorded on the
screening computer system. Followup of the 85 assessed
benign women who did not have reinvitation appointments
recorded on the computer system (Table 2) revealed that
at least 35 of them (41%) had been offered reinvitation
appointments, which they had cancelled in advance. The
reduced reattendance among assessed women would not
have been apparent had the analysis investigated the pro-
portions of women with recorded reinvitation appoint-
ments who returned, since reattendance among those
with recorded reinvitation appointments was similarly high
in all women (around 94%), regardless of assessment
history. Furthermore, such analysis would have failed to
reveal the correct magnitude of the increased risk of
cancer among women undergoing false-positive mammo-
graphy, since the OR for an interval cancer arising in all
assessed women versus that in nonassessed women was
3.19 (95% CI, 2.34–4.35). This OR fell to 1.21 (95% CI,
0.49–2.97) when only those women with recorded re-
invitation appointments within 3.5 years were considered
(data not shown). Regardless of whether the lack of
recorded reinvitation appointments is due to an active
choice on the part of women not to attend or due to a
failure of the system to reinvite them, the fact that they are
not being rescreened yet they are at increased risk of
cancer is clearly of great concern.
False-positive mammography, leading to unnecessary
assessment of disease-free women, has associated costs.
First, there are the psychological costs of inconvenience
and increased anxiety in women unnecessarily recalled
[5,33,34]. Second, there are the direct financial costs to
the health service of unnecessary procedures [35,36].
Third, there are the overall costs to the invited population
of the reduced effectiveness of screening [11]. East
Anglian women undergoing false-positive first mammo-
graphy were more likely to present with cancer and less
likely to reattend for a second screen. The impact of
nonreattendance on potential subsequent mortality reduc-
tion is not insignificant since, for those who do not re-
attend, the stage of any subsequently diagnosed cancers
will be shifted from earlier, when detected by screening, to
later, when presenting symptomatically in lapsed attenders.
Available online http://breast-cancer-research.com/content/4/5/R11
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and then presented with an interval or screen-detected
cancer, the current study indicated that these cancers
were more likely to measure 20+ mm and to be of a higher
stage than those in nonassessed women, and second
screen-detected cancers were more likely to be node pos-
itive. This indicates a poorer prognosis for women who
presented with cancer having undergone false-positive
mammography, although when assessed by histological
subtype and grade such cancers were apparently of lower
prognostic risk than those in nonassessed women. The
reasons for this inconsistency are unclear.
The current findings relate to women assessed at first
screen within the East Anglia screening programme,
carried out over the period 1989–1995. With technical
improvements to the programme and women’s increased
familiarity with it, reduced reattendance and increased risk
of cancer may be less associated with false-positive mam-
mography at first screen. Furthermore, the impact of false-
positive mammography may be lower after a second or
subsequent screening. Fewer women are assessed at
second and subsequent screens [37,38], possibly due to
the increase in specificity associated with the availability of
previous films for comparison [39]. Finally, it should be
noted that, while there was increased risk of subsequent
cancer associated with women assessed at first screen,
such women contributed only a modest proportion of all
interval and second round screen-detected cancers.
Conclusions
False-positive mammography in the first screening round
in East Anglia was associated both with increased risk of
interval cancers and cancer detected at second screen-
ing, and with reduced reattendance at subsequent
screens. If these associations persist within the screening
programme, then efforts must be made to identify the
factors predisposing certain women to false-positive mam-
mography, to encourage continued participation, and to
detect any subsequent cancers at the earliest possible
opportunity.
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